

April 15, 2014

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 10122-edited).

**Title:** Novel treatment approaches in hypertensive type two diabetic patients.

**Author:** Yaniel Castro Torres, Richard E. Katholi

**Name of Journal:** World Journal of Diabetes

**ESPS Manuscript No: 10122**

Revisions made based on the helpful suggestions of reviewer 00211910:

- (1) Further language polishing was done to improve understanding.
- (2) Figure 1 was added showing antihypertensive mechanisms of carvedilol and RDN.
- (3) Figure 2 was added showing proposed mechanisms to explain decreased insulin resistance with carvedilol and RDN.

Revisions made based on the helpful suggestions of reviewer 00502799:

- (1) The Introduction has been revised and Perspective section greatly expanded to clarify why the review focuses on carvedilol and RDN as potential therapies for patients with HTN and T2DM. These sections also note current guidelines and emphasize that carvedilol and RDN need further study before becoming standard recommended therapies.
- (2) Carvedilol and RDN were chosen for review and comparison because both are lowering blood pressure and improving insulin sensitivity through an attenuation of sympathetic nervous system activity.
- (3) The title has been changed as recommended. The Perspective section now includes discussion of choices of antihypertensive medicines and effects on glucose metabolism to emphasize how carvedilol and /or RDN may be useful future options to achieve guideline goals. The potential effects of carvedilol on masking hypoglycemia or worsening symptoms in patients with peripheral vascular disease are discussed. Throughout the review it has been emphasized that choice of therapy needs to be individualized.
- (4) Our reason for noting that there is a lack of evidence in terms of the long term effects of carvedilol and RDN on relevant clinical endpoints in hypertensive patients with T2DM is to keep these potential novel therapies in perspective but also stimulate further study.

Thank you again for publishing our manuscript in the World Journal of Diabetes.

Sincerely,

Richard E. Katholi, MD

Southern Illinois University School of Medicine

Prairie Cardiovascular Consultants

619 E. Mason St., Ste 4P57

Springfield, IL 62701, USA

W) 217-788-0706

Fax: 217-757-6502

E-mail: [rkatholi@prairieheart.com](mailto:rkatholi@prairieheart.com)